Navigation Links
Phylonix granted broad European patent for transplanting human cells into zebrafish
Date:12/18/2007

Cambridge, MA -- December 18, 2007 -- Phylonix Pharmaceuticals today announced that it recently received a broadly issued European patent EP 1 135 531 B1: Methods for Introducing Heterologous Cells into Fish. The patent, which has issued in key European countries, encompasses 68 claims, including transplanting stem cells, cancer cells and pathogens. In addition, neurons, chondrocytes, renal and hepatic cells can be transplanted in zebrafish and effects of growth factors or cytotoxic agents can be assessed. Claims also cover recovering cells for potential tissue engineering or transplantation applications. Many of these claims have issued previously in the United States and other countries.

This award complements our previously issued patents for assessing angiogenesis, apoptosis and toxicity in zebrafish, and use of high-throughput screening methods such as microplate analysis, commented Patricia McGrath, Phylonix President and Chief Executive Officer.

Cells that proliferate in their native environment also proliferate when transplanted into zebrafish; cells that are incapable of proliferating in their native environment usually do not proliferate in zebrafish.

Advantages of Zebrafish for Transplantation

Currently, the mouse is the model system of choice for cell transplantation assays. However, to prevent cell rejection, transplantation of human cells must be performed using immunosuppressed mice and these animals are expensive to develop and maintain. In comparison, cell transplantation in zebrafish larvae is simple and cost effective, and immunosuppression is not necessary.

There are several additional advantages of using zebrafish for transplantation assays. All essential components of vertebrate form and organ development are mimicked in the transparent zebrafish and their molecular basis is either identical or similar, underscoring the potential for use in research on human diseases. Due to the small size of zebrafish larvae, it is possible to rapidly analyze and or recover transplanted cells. Zebrafish larvae are transparent facilitating direct microscopic observation of a number of physiological processes within the cells. Zebrafish can be cultured in solution facilitating contacting transplanted cells with drugs or growth factors. Microliters of drug are required for zebrafish compared with milliliters per mouse. Standard microtiter plate readers can be used for measurement, making this format particularly attractive for high throughput drug screening. Phylonix and others have demonstrated that for many compounds, results in zebrafish correlate with results in other animal models as well as with results in humans.


'/>"/>

Contact: Edward O'Lear
ed.olear@phylonix.com
617-441-6700
Phylonix Pharmaceuticals
Source:Eurekalert

Related medicine news :

1. NIH awards Phylonix phase II SBIR to develop zebrafish models for eye diseases
2. PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
3. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
4. USC granted $8.4 million for autism research
5. Aida Granted Additional Anti-Cancer Patent
6. CME LLC Granted Five-Year Full Approval by the American Psychological Association
7. ActiPatch(TM) Granted Market Clearance by the Food & Drug Administration in the Kingdom of Jordan
8. TREANDA New Drug Application for the Treatment of Chronic Lymphocytic Leukemia Granted Priority Review Status by FDA
9. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
10. Isis Announces ISIS 333611 Granted Orphan Drug Status for Treatment of ALS
11. Broad-based group of physicians calls for improvement in stroke treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... Secure Exchange Solutions, the leading ... of hospitals, health information exchanges, physicians and patients, announced today that SES Direct ... Edition Health IT Module Certification via Drummond Group LLC, an Authorized Certification Body ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... leads to fewer trips the emergency room, fewer hospital admissions, and better blood ... of Managed Care® (AJMC®) finds. The study can be found here . ...
(Date:2/22/2017)... Fla. (PRWEB) , ... February 22, 2017 , ... ... is just as effective on smaller and sometimes harder to reach ones, according ... were presented at the International Stroke Conference in Houston by Ricardo A. Hanel, ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... newest advanced absorption cannabidiol (CBD) serum, “NANOCALM 300” Microemulsified Hemp Extract. This ... instant absorption from the mouth into the bloodstream. Far outpacing the ...
(Date:2/22/2017)... ... February 22, 2017 , ... ANGLESTRONG , the new recovery management ... on the App Store and Google Play . Florida-based Sober Network, ... and recovery industry, partnered with Angle to build ANGLESTRONG. The new recovery management app ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... 22, 2017 According to a new market ... SIMS, CUSCO), Application (Laparoscopy, Colposcopy, Hysteroscopy, D&C, Ablation, Biopsy), & End ... published by MarketsandMarkets, the global market is expected to reach USD ... a CAGR of 7.1% during the forecast period. ... ...
(Date:2/22/2017)... PORTLAND, Oregon and PUNE, India ... report published by Allied Market Research, titled, "Automated Radio Synthesis ... that the world automated radiosynthesis modules market was worth $20 ... 2022, growing at a CAGR of 6.6% from 2016 to ... largest share in terms of both market revenues and unit ...
(Date:2/22/2017)... Conn. , Feb. 22, 2017   Protein ... maker of Flublok® Influenza Vaccine , announced today ... Partnership for Influenza Vaccine Introduction (PIVI) and the Mongolian ... devastating impacts of the flu.  The doses of Flublok ... Mongolia for health care workers, ...
Breaking Medicine Technology: